1 research outputs found
New Antipsychotics
Antipsihotici, Ŕto su se pojavili na tržiŔtu nakon
klozapina, a sintetizirani su na temelju opaženog kliniÄkog
uÄinka i farmakoloÅ”kog profila djelovanja klozapina, nazivani
su razliÄito: ānoviji antipsihoticiā, ānovi antipsihoticiā, āatipiÄni
antipsihoticiā i āantipsihotici druge generacijeā. Naziv
antipsihotici druge generacije (ADG) po svemu sudeÄi najprikladniji
je pa je uglavnom i prihvaÄen kad se govori o ovoj heterogenoj
skupini lijekova Å”to se kliniÄki rabe za gotovo iste
indikacije. Razlozi za takav stav leže u Äinjenicama da je,
prvo, upitno je li razlikovanje tipiÄnih i atipiÄnih antipsihotika
znanstveno opravdano. Nadalje, ni svi ovi lijekovi nisu viŔe
novi (ili noviji), niti farmakoloÅ”ki ili kliniÄki identiÄni, veÄ imaju
razliÄite farmakoloÅ”ke i kliniÄke uÄinke. MeÄutim, ostaje
Äinjenica da su svi oni pripadnici druge generacije antipsihotiÄkih
lijekova. Ovdje Äe se opisati: amisulprid, klozapin,
olanzapin, kvetiapin, risperidon, sertindol, ziprasidon, zotepin
i aripiprazol koji su do sada licencirani u bar jednoj zemlji
Europske unije ili u Sjedinjenim AmeriÄkim Državama, i
iloperidon koji je u zadnjoj fazi kliniÄkog ispitivanja.Antipsychotics that emerged on the market
after clozapine, synthesized on the basis of observed clinical
efficacy and pharmacological profile of clozapine activity, have
got various names: ānewer antipsychoticsā, ānew antipsychoticsā,
āatypical antipsychoiticsā and āsecond generation
antipsychoticsā. The name āsecond generation antipsychoticsā
(SGA) is, according to all data, the most appropriate, so it has
become generally accepted when speaking about this heterogeneous
group of medications, which is clinically used for
almost identical indications. Reasons for such attitude lie in the
facts that it is questionable whether the distinction between typical
and atypical antipsychotics is scientifically justified. Furthermore,
all these drugs are not new (or newer) any more, and are
not pharmacologically and clinically identical, but have different
pharmacological and clinical efficacy. However, the fact remains
that they all belong to the second generation of antipsychotic
drugs. Here are described: amisulpride, clozapine, olanzapine,
quetiapine, risperidone, sertindole, ziprasidone, zotepine and
aripiprazole, up to now licensed in at least one country of the
European Union or in the USA, as well as iloperidone, which is
in the final phase of clinical research